Osteoarthritis (OA) is the most common cause of disability in older adults. It is characterised by joint pain and/or joint dysfunction, and high interpatient variability. Until recently, treatment has focussed only on symptom control, meaning that the condition worsens over time, often leading to arthroplasty. A growing understanding of the pathophysiological processes underlying the condition have elucidated novel therapeutic targets, including inflammatory cytokines, matrix-degrading enzymes, mTOR signalling pathways and the Wnt pathway. Repurposing existing drugs such as metformin and statins for the treatment of OA is also being explored. Personalized OA therapy is the ultimate goal, with recent advances in
phenotype classification and numerous emerging targeted therapies offering hope for the future.
Ruth Wittoek, ACR 2022: Findings from the phase 2 study of denosumab in erosive hand osteoarthritis
Denosumab, a RANK ligand inhibitor that reduces osteoclast formation and bone resorption, was investigated in a randomized, double blind, placebo-controlled phase 2 study in patients with erosive hand osteoarthritis (EUDRACT CT 2015-003223-53). touchIMMUNOLOGY were delighted to speak with Dr. Ruth Wittoek (Ghent University, Ghent, Oost-Vlaanderen, Belgium) around the rationale for the use of denosumab in […]
Nancy Lane, ACR 2022: Romosozumab for knee osteoarthritis in postmenopausal women – findings from a substudy of the FRAME clinical trial
The FRAME clinical trial (NCT01575834) was a phase 3 randomised, double-blind, placebo-controlled study, that investigated the efficacy and safety of romosozumab in postmenopausal women with osteoporosis (OP); the knee osteoarthritis (OA) substudy assessed the effect of treatment with romosozumab on the progression of OA of the knee in women with OP and knee OA. In […]
Nancy Lane, ACR 2022: A phase 2 study of lorecivivint injections for the treatment of knee osteoarthritis
Lorecivivint is an intra-articular CLK/DYRK inhibitor recently studied in a phase 2 clinical trial for the treatment of knee osteoarthritis (NCT03727022). In this touchIMMUNOLOGY interview, we caught up with Dr. Nancy Lane (University of California Davis, Sacramento, CA, USA) to discuss the aims, design, eligibility criteria and efficacy and safety findings of the study. This […]
Osteoarthritis: Advances and Emerging Treatments
touchREVIEWS in RMD. 2022;1(2):57–60 DOI: https://doi.org/10.17925/RMD.2022.1.2.57
Globally, osteoarthritis (OA) is the most common joint condition, affecting 10% of men and 18% of women over the age of 60 years.1 OA represents a group of overlapping disease processes of differing aetiologies, all of which cause a pattern of degenerative disorder of the synovial joints. Classical radiological findings associated with a diagnosis of OA […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!